Tocilizumab: Therapy and safety management
References (136)
- et al.
Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with anlylosing spondylitis or psoriatic arthritis : 2007 update
Joint Bone Spine
(2007) - et al.
Cardiovascular risk and rheumatoid arthritis: clinical practice guide- lines based on published evidence and expert opinion
Joint Bone Spine
(2006) Cardiovascular risk in rheumatoid arthritis
Autoimmun Rev
(2009)- et al.
Effect of Interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebocontrolled, randomised trial
Lancet
(2008) - et al.
The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting
J Clin Virol
(2008) - et al.
Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma
Blood
(2006) - et al.
Systematic review of the association between circulating interleukin-6 (IL-6) and cancer
Eur J Cancer
(2008) - et al.
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Trends Mol Med
(2008) - et al.
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis
Cell
(2005) - et al.
Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study
Eur J Cancer
(1998)
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use
Gastroenterology
(2003)
Complications of colonic diverticular disease during rheumatoid polyarthritis: 7 cases
Rev Med Interne
(1999)
Antibiotic prophylaxis in dentistry: a review and practice recommendations
JADA
(2000)
Juvenile Idiopathic Arthritis
Lancet
(2007)
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
Lancet
(2008)
Rituximab (Mabthera®) therapy and safety management
Joint Bone Spine
(2008)
Abatacept therapy and safety management
Joint Bone Spine
(2009)
Predicting cardiovascular risk in England and Wales: pros- pective derivation and validation of QRISK2
BMJ
(2008)
Long-term safety and tolerability of tocilizumab treatment in patients with rheumatoid arthritis and mean treatment duration of 2.4 years (Concurrent Abstract Session)
Arthritis Rheum
(2009)
Lipid and Inflammatory Biomarker Profiles in Patients Receiving Tocilizumab for Rheumatoid Arthritis: Analysis of Five Phase 3 Clinical Trials (Abstract)
Arthritis Rheum
(2008)
Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis with Elevated Low Density Lipoprotein Cholesterol: Analysis of Five Phase 3 Clinical Trials (Abstract)
Arthritis Rheum
(2008)
Cardiovascular biology of interleukin-6
Curr Pharm Des
(2009)
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review
PLoS Med
(2008)
Common inflammatory mediators orchestrate pathophysiological processes in rheu- matoid arthritis and atherosclerosis
Rheumatology
(2009)
Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies
Arthritis Rheum
(2008)
Evaluation de la prévalence des facteurs de risque cardiovasculaire classiques au cours de la polyarthrite rhumatoïde
Rev Rhum
(2008)
Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions
Ann Rheum Dis
(2009)
Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis
Arthritis Res Ther
(2008)
Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis
Rheumatology
(2007)
Patient education on cardiovascular aspects of rheumatoid disease: an unmet need
Rheumatology
(2007)
Rheumatoid arthritis versus diabetes as a risk factor for cardio- vascular disease: a cross-sectional study, the CARRE Investigation
Ann Rheum Dis
(2009)
Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis
Curr Vasc Pharmacol
(2008)
Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA?
Heart
(2009)
An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice
Rheumatology
(2009)
Neutropenia induced by anti-interleukin-6 receptor antibody, tocilizumab
Ann Rheum Dis
(2009)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebocontrolled trial
Arthritis Rheum
(2004)
Long-term safety and efficacy of tocilizumab, an anti-inter- leukin-6 receptor monocolonal antibody in monotherapy, in patients with rheumatoid arthritis (the STREAM Study) : evidence of safety and efficacy in a 5-year extension study
Ann Rheum Dis
(2009)
Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist. Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate
Arthritis Rheum
(2006)
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Mod Rheumatol
(2009)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray eader-blinded randomised controlled trial of tocilizumab
Ann Rheum Dis
(2007)
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
Arthritis Rheum
(2008)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics : results from a 24-week multicentre randomised placebo controlled trial
Ann Rheum Dis
(2008)
Safety and tolerability of tocilizumab in combination with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX : 1-year results of the LITHE study
EULAR
(2009)
Cited by (55)
Efficacy and tolerance of Tocilizumab in off-label use in autoimmune diseases: A French multicenter study
2020, Revue du Rhumatisme (Edition Francaise)Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
2020, European Journal of Internal MedicineNeonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives
2020, Pharmacological ResearchPractical Pearls About Current Rheumatic Medications
2018, Primary Care - Clinics in Office PracticeCitation Excerpt :Lower intestinal perforations have also occurred with tocilizumab, and its use is contraindicated in patients with increased risk or previous perforation.85,86 Tocilizumab alters the therapeutic effects of benzodiazepines, warfarin, atorvastatin, calcium channel inhibitors, cyclosporine, phenytoin, and theophylline.85 Although only approved for use in RA and antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis, rituximab has multiple off-label uses as demonstrated in Table 11.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.